Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?

BACKGROUND: In China, health technology assessment (HTA) has recently been adopted in pricing negotiation for medicine listing in the National Reimbursement Drug List. At present, how HTA is applied to inform the decision-making process remains underreported. In order to explore how the adoption of...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Cong, Ung, Carolina Oi Lam, Wushouer, Haishaerjiang, Bai, Lin, Huang, Tao, Li, Xinyi, Guan, Xiaodong, Shi, Luwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722031/
https://www.ncbi.nlm.nih.gov/pubmed/34980159
http://dx.doi.org/10.1186/s12961-021-00810-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722031/
https://www.ncbi.nlm.nih.gov/pubmed/34980159
http://dx.doi.org/10.1186/s12961-021-00810-1

Ejemplares similares